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ABSTRACT 35 
Recent studies have shown that the hypothalamic neuropeptide 26RFa regulates glucose 36 
homeostasis by acting as an incretin, and increasing insulin sensitivity. In this study, we 37 
further characterized the role of the 26RFa/GPR103 peptidergic system in the global 38 
regulation of glucose homeostasis using a 26RFa receptor antagonist, and also assessed 39 
whether a dysfunction of the 26RFa/GPR103 system occurs in obese hyperglycemic mice. 40 
Firstly, we demonstrate that administration of the GPR103 antagonist reduces the global 41 
glucose-induced incretin effect and insulin sensitivity whereas, conversely, administration of 42 
exogenous 26RFa attenuates glucose-induced hyperglycemia. Using a mouse model of high-43 
fat diet-induced obesity and hyperglycemia, we found a loss of the anti-hyperglcemic effect 44 
and insulinotropic activity of 26RFa, accompanied with a marked reduction of its insulin-45 
sensitive effect. Interestingly, this resistance to 26RFa is associated with a down-regulation of 46 
the 26RFa receptor in the pancreatic islets, and insulin target tissues. Finally, we observed that 47 
the production and release kinetics of 26RFa after an oral glucose challenge is profoundly 48 
altered in the high-fat mice. Altogether, the present findings support the view that 26RFa is a 49 
key regulator of glucose homeostasis whose activity is markedly altered under 50 
obese/hyperglycemic conditions. 51 
 52 
Key words: 26RFa; incretin; glucose homeostasis; diabetes; obesity 53 
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INTRODUCTION 55 
 56 
The neuropeptide 26RFa, also referred to as QRFP (for pyroglutamilated RFamide 57 
peptide), is the latest member of the RFamide peptide family discovered (5,9,16). 26RFa and 58 
its N-extended form 43RFa were identified as the cognate ligands of the human orphan G-59 
protein-coupled receptor, GPR103 (6,9,16,30). This peptidergic system is abundantly 60 
expressed in the hypothalamus and is involved in the control of feeding behaviour (3,4,5,30). 61 
Indeed, 26RFa (or 43RFa) stimulates food intake (5,20,21,30), and the neuropeptide exerts its 62 
orexigenic activity via a modulation of the NPY/POMC network in the arcuate nucleus (20). 63 
These observations have been recently confirmed by data obtained from 26RFa-deficient mice 64 
showing that the knockout (KO) mice are lean and hypophagic, and that, under a high-fat 65 
(HF) diet, the 26RFa KO mice show a lower weight gain than the wild-type animals (22). In 66 
line with this, a more sustained orexigenic activity of 26RFa/43RFa has been reported in wild 67 
type mice submitted to a HF diet (21,27). Moreover, the expression of prepro26RFa mRNA is 68 
up-regulated in the hypothalamus of genetically obese ob/ob and db/db mice, and rodents 69 
submitted to a HF diet (27,30). Altogether, these findings support the notion that 26RFa could 70 
play a role in the development and maintenance of the obese status (7). 71 
Accumulating evidence over the last decade supports the role of neuropeptides controlling 72 
feeding behavior such as neuropeptide Y (NPY), orexins, ghrelin, corticotropin-releasing 73 
factor (CRF) or apelin, in the peripheral regulation of glucose homeostasis (14,15,23,32,33). 74 
This has led to the new concept that hypothalamic neuropeptides may serve as a link between 75 
energy and glucose homeostasis, and therefore, they represent potential therapeutic targets for 76 
the treatment of diabetes and obesity (28,29).  In this context, the potential role of 26RFa in 77 
the control of glucose homeostasis was investigated. It was found that 26RFa/43RFa and 78 
GPR103 are expressed in pancreatic islets, as well as in various insulin-secreting cell lines 79 
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(11,26), and that 26RFa and 43RFa prevent cell death and apoptosis of β cell lines and 80 
isolated human pancreatic islets (11). It has been shown that 26RFa is abundantly expressed 81 
by the gut and that i.p. administration of the neuropeptide attenuates glucose-induced 82 
hyperglycemia by increasing plasma insulin via a direct insulinotropic effect on the pancreatic 83 
β cells, and also by increasing insulin sensitivity (26).  Furthermore, it was reported that an 84 
oral glucose challenge induces a massive secretion of 26RFa by the gut into the blood, 85 
strongly suggesting that this neuropeptide plays an important role in the regulation of 86 
glycemia by acting as an incretin (26). 87 
The incretin effect is known to be markedly reduced in diabetic patients (18), although 88 
most studies have reported that levels of GLP-1 and gastric inhibitory polypeptide (GIP) in 89 
response to oral glucose were similar in diabetic and non-diabetic subjects (8,13,18). This 90 
incretin defect is notably characterized by a decreased, albeit partially preserved, 91 
insulinotropic potency of GLP-1 and an almost complete loss of insulin secretion to GIP (18). 92 
In this context, the objective of the present study was twofold: (1) to further characterize the 93 
role of 26RFa/GPR103 peptidergic system in the global regulation of glucose homeostasis 94 
(via an oral glucose tolerance test) using a 26RFa receptor antagonist (namely 25e) (10); and 95 
(2) to determine whether a dysfunction of the 26RFa/GPR103 system occurs in 96 
obese/hyperglycemic conditions.  97 
  98 
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MATERIAL AND METHODS 99 
 100 
Animals. Male C57Bl/6 mice (Janvier laboratory, Le Genest-Saint-Isle, France), weighing 101 
22–25 g, were housed at 5 animals per cage, with free access to standard diet (U.A.R., 102 
Villemoisson-sur-Orge, France) and tap water. They were kept in a ventilated room at a 103 
temperature of 22±1°C under a 12-h light/12-h dark cycle (light on between 7 h and 19 h). All 104 
the experiments were carried out between 09.00 h and 18.00 h in testing rooms adjacent to the 105 
animal rooms. Animal manipulations were performed according to the European Community 106 
Council Directive of November 24th 1986 (86:609: EEC), and were conducted by authorized 107 
investigators.  108 
High-fat (HF) model. Mice were submitted to a dietary challenge at two months of age by 109 
using a standard chow (U8200G10R; energy density: 2 830 kcal/kg; Scientific Animal Food 110 
& Engineering (SAFE), Augy, France) or a HF diet (U8978; energy density: 5 283 kcal/kg; 111 
SAFE). Experiments were performed after three months of dietary challenge. Our Institutional 112 
Animal Use and Care Committee (CENOMAX, Agreement of the Ministry of Research n°54) 113 
approved the experimental procedures (Agreement n°: #11752). 114 
Peptides and chemicals. Mouse 26RFa (ASGPLGTLAEELSSYSRRKGGFSFRF-NH2) 115 
was synthezised (0.1 mmol scale) by the solid phase methodology on a Rink amide 4-116 
methylbenzhydrylamine resin (Biochem, Meudon, France) by using a 433A Applied 117 
Biosystems peptide synthesizer and the standard fluorenylmethoxycarbonyl (Fmoc) 118 
procedure. The synthetic peptide was purified by reversed-phase HPLC on a 2.2 × 25-cm 119 
Vydac 218TP1022 C18 column (Alltech, Templemars, France) by using a linear gradient  (10-120 
50% over 50 min) of acetonitrile/trifluoroacetic acid (99.9 : 0.1 ; v/v) at a flow rate of 10 121 
mL/min. Analytical HPLC, performed on a Vydac 218TP54 C18 column (0.46 × 25-cm), 122 
showed that the purity of the peptides was greater than 99%. The identity of the synthetic 123 
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peptide was confirmed by mass spectrometry on a JEOL model AX-500 mass spectrometer. 124 
The GPR103 antagonist 25e was synthesized as previously described (10). Insulin and 125 
exenatide were purchased from Eli Lilly (Neuilly-sur-Seine, France). 126 
Blood glucose and insulin measurements in mice. For i.p. glucose tolerance test and 127 
glucose-stimulated insulin secretion assay, mice were fasted for 16 h with free access to water 128 
and then injected i.p. with glucose (1.5 g/kg) and 26RFa (500 μg/kg) or PBS solution. For 129 
measurements of basal glycemia, mice were fed ad libitum and injected i.p. with 26RFa (500 130 
μg/kg) or PBS solution. Blood plasma glucose concentrations were measured from tail vein 131 
samplings at various times using an AccuChek Performa glucometer (Roche Diagnostic, 132 
Saint-Egreve, France). Plasma insulin concentrations were determined using an AlphaLISA 133 
insulin detection kit (ref AL204c, Perkin Elmer, Courtabeuf, France). For insulin tolerance 134 
test, mice were fasted for 6 h and injected i.p. with 0.75 units/kg body weight of human 135 
insulin (Eli Lilly, Neuilly-sur-Seine, France) and 26RFa (500 μg/kg) or the GPR103 136 
antagonist 25e (5 mg/kg), or PBS. For oral glucose tolerance test, mice were fasted for 16 h 137 
before the test with free access to water and injected i.p. with the GPR103 antagonist 25e (5 138 
mg/kg) or PBS 30 min before a 2 g/kg oral glucose load. For the experiments with 26RFa, the 139 
peptide (500 μg/kg) was injected (i.p.) just before the glucose load.  Blood plasma glucose 140 
and insulin concentrations were measured from tail vein samplings at various times and 141 
plasma samples for 26RFa concentration measurements were obtained from decapitation just 142 
before or 30 and 120 min after the glucose challenge, and then assayed for 26RFa. 143 
Insulin secretion by the EndoC-βH1 cells. Human β cells (EndoC-βH1), a kind gift from 144 
Dr R. Scharfmann (INSERM U1016, Institut Cochin, Paris, France), were grown in DMEM 145 
containing 2.8 mM glucose and supplemented with 2% heat-inactivated fetal bovine serum, 2-146 
mercaptoethanol (50 µM), nicotinamide (10 mM), selenite sodium (6.7 ng/ml), transferin (5.5 147 
µg/ml), penicillin (100 mg/l) and streptomycin (100 mg/l), in a humidified atmosphere of 5% 148 
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CO2, 95% air at 37° C. Concurrently, some wells containing the EndoC-βH1cells were 149 
incubated in the same medium containing a solution of palmitate (10 mM, P9767-5G, Sigma 150 
Aldrich) for four days. Before the experiments, the culture medium was removed and EndoC-151 
βH1 cells (4.3x105 cells/well) were preincubated in a Krebs-Ringer bicarbonate buffer 152 
containing 0.2% BSA and 2.8 mM glucose (low glucose, LG) for 1 h at 37° C (period P1) to 153 
evaluate basal insulin secretion. The culture medium was then removed and replaced by the 154 
same culture medium (LG) or a culture medium with 16.5 mM of glucose (high glucose, HG) 155 
added or not with 26RFa (10-6 M) and the GLP-1 analogue exenatide (5 10-7 M) for 1 h 156 
(period P2). Insulin secreted in the culture medium was measured using a commercial ELISA 157 
kit (Mercodia Insulin ELISA, Uppsala, Sweden) and was expressed as the ratio between 158 
secretion during the P2 period/secretion during the P1 period. 159 
Immunohistochemical procedure. Deparaffinized sections (15-µm thick) of duodenum and 160 
pancreas of control or HF mice were used for immunohistochemistry. Tissue sections were 161 
incubated for 1 h at room temperature with rabbit polyclonal antibodies against 26RFa (3) 162 
diluted 1:400 or GPR103 (#NLS1922; Novus Biologicals, Littletown, CO) diluted 1:100. The 163 
sections were incubated with a streptavidin-biotin-peroxydase complex (Dako Corporation, 164 
Carpinteria, CA), and the enzymatic activity was revealed with diaminobenzidine. Some 165 
slices were then counterstained with hematoxylin. Observations were made under a Nikon E 166 
600 light microscope.  167 
Quantitative PCR. Total RNA from the skeletal muscle, adipose tissue, liver and 168 
duodenum of HF and control mice, and from EndoC-βH1 cells was isolated as previously 169 
described (25). Relative expression of the 26RFa, GPR103, GLP-1 receptor, GLUT-1 and 170 
GLUT-2 genes was quantified by real-time PCR with appropriate primers (Table 1). GAPDH 171 
or cyclophilin A were used as internal controls for normalization. PCR was carried out using 172 
Gene Expression Master Mix 2X assay (Applied Biosystems, Courtaboeuf, France) in an ABI 173 
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Prism 7900 HT Fast Real-time PCR System (Applied Biosystems). The purity of the PCR 174 
products was assessed by dissociation curves. The amount of target cDNA was calculated by 175 
the comparative threshold (Ct) method and expressed by means of the 2-ΔΔCt method. 176 
26RFa radioimmunoassay. Quantification of 26RFa in plasma and tissue samples was 177 
carried out using a specific radioimmunoassay (RIA) set up in the laboratory that has been 178 
previously described in detail (3). For the RIA procedure, each plasma sample was diluted 179 
(1:1) in a solution of water/TFA (99.9:0.1; v/v). The duodenum fragments were immersed for 180 
15 min in boiling 0.5 M acetic acid, homogenized at 4°C using a glass potter homogenizer 181 
and centrifuged (6,000 g, 4°C, 30 min). Diluted plasma and supernatant fluid of tissue extracts 182 
were pumped at a flow rate of 1.5 ml/min through one Sep-Pak C18 cartridge. Bound material 183 
was eluted with acetonitrile/water/TFA (50:49.9:0.1; v/v/v) and acetonitrile was evaporated 184 
under reduced pressure. Finally, the dried extracts were resuspended in PBS 0.1 M and 185 
assayed for 26RFa. 186 
Statistical analysis.  Statistical analysis was performed with Statistica (5th version). A 187 
student t-test or ANOVA for repeated measures were used for comparisons between two 188 
groups. A post-hoc comparison using Tukey HSD was applied according to ANOVA results. 189 
Statistical significance was set up at p < 0.05.  190 
 191 
192 
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 RESULTS 193 
 194 
Consequence of blocking 26RFa action on glucose and insulin tolerance in control mice. 195 
Administration of the 26RFa receptor antagonist, 25e, 30 min before an oral glucose tolerance 196 
test resulted in a significant increase of the glycemia between 30 and 60 min after the oral 197 
glucose challenge (Fig. 1A), as assessed by the calculation of the areas under the curve (Fig. 198 
1A insert). Plasma insulin concentrations tended to be slightly higher in animals that received 199 
the GPR103 antagonist, but without reaching the statistical significance (Fig. 1B).  200 
Administration of 25e during an insulin tolerance test significantly reduced insulin 201 
sensitivity from 15 to 90 min after the i.p. injection of insulin (p<0.05-p<0.001) (Fig. 1C) as 202 
assessed with a statistical difference of the areas under the curve of p=0.07 between 25e-203 
treated mice and animals that did not receive the GPR103 antagonist (Fig. 1C insert). 204 
Effect of a 26RFa injection on blood glucose and plasma insulin levels following an oral 205 
glucose challenge.  206 
We completed the experiments using the 26RFa receptor antagonist, by performing oral 207 
glucose tolerance tests with administration of exogenous 26RFa. In these experiments, the 208 
hyperglycemic effect induced by the glucose challenge was significantly reduced by the i.p. 209 
injection of 26RFa (Fig. 1D), but without any significant alteration of plasma insulin levels 210 
(Fig. 1E). 211 
Effect of 26RFa on basal glycemia, glucose-induced hyperglycemia and insulin tolerance. 212 
The high-fat (HF) diet challenge induced a significant (p<0.001) weight gain right from the 213 
first month of treatment (Fig. 2A). After three months, the HF mice exhibited a weight of 214 
43.00 ± 0.65 g, whereas mice fed a standard chow weighted 27.00 ± 0.85 g (Fig. 2A). 215 
Similarly, plasma glucose was significantly increased (p<0.01) after one month of HF diet 216 
(Fig. 2B). After 3 months, the HF mice exhibited a fasting glycemia of 2.11 ± 0.06 g/l, 217 
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whereas that of the mice fed a standard chow at the same time was 1.16 ± 0.05 g/l (p<0.001; 218 
Fig. 2B).  219 
The impact of 26RFa was investigated on basal glycemia in mice fed a standard chow and 220 
in HF mice. As illustrated in figure 2C, D, i.p. administration of 26RFa did not affect 221 
significantly basal plasma glucose levels during the 90-min period of the test in the two diet 222 
conditions. By contrast, an IPGTT performed in the two groups of mice revealed that 26RFa 223 
significantly attenuated (p<0.05) the hyperglycemia induced by an i.p. glucose challenge in 224 
mice fed a standard chow during the first 30 min of test, whereas this anti-hyperglycemic 225 
effect of the neuropeptide was totally abolished in HF mice (Fig. 2E, F). I.p. injection of 226 
26RFa also significantly potentiated (p<0.05) insulin-induced hypoglycemia during the 90 227 
min following the insulin challenge in mice fed a standard chow as illustrated by the 228 
quantification of the areas under the curves (Fig. 3A, C). By contrast, the beneficial effect of 229 
26RFa on insulin sensitivity was strongly attenuated in HF mice (Fig. 3B, C). Quantification 230 
of GPR103 mRNA in insulin target tissues revealed a significant decrease (p<0.05) in the 231 
expression of the 26RFa receptor in the muscle and the adipose tissue of HF mice (Fig. 3D). 232 
No expression of GPR103 was detected in the liver of the two groups of animals (Fig. 3D). 233 
Consequence of blocking 26RFa action on glucose and insulin tolerance in HF mice. 234 
Administration of the GPR103 antagonist 25e during an oral glucose tolerance test in HF 235 
mice had no significant effect on plasma glucose and insulin levels (Fig.  4A, B) in contrast to 236 
what was observed in mice fed a standard chow (Fig. 1A, B). i.p. injection of 25e had no 237 
significant impact on insulin sensitivity during an insulin tolerance test in HF mice (Fig. 4C) 238 
in contrast to the insulin-resistant effect of the GPR103 antagonist observed in mice fed a 239 
standard chow (Fig. 1C). In addition, administration of 26RFa had no effect on the 240 
hyperglycemia induced by the oral glucose load (Fig. 4D) nor on plasma insulin levels (Fig. 241 
4E). 242 
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Effect of 26RFa on insulin production. The effect of 26RFa on insulin production was 243 
investigated in vivo and in vitro. An acute glucose-stimulated insulin secretion test showed 244 
that injection of 26RFa significantly stimulated glucose-induced insulin production in mice 245 
fed a standard chow (p<0.05; Fig. 5A), whereas this insulinotropic effect of the neuropeptide 246 
was totally abolished in HF mice (Fig. 5B). Concurrently, the impact of 26RFa on insulin 247 
secretion by pancreatic β cells was examined using the human insulin-secreting cell line, 248 
EndoC-βH1, that were treated with palmitate to mimic conditions of lipotoxicity.  As 249 
illustrated in figure 5C, addition of 26RFa in the culture medium significantly stimulated 250 
insulin secretion by untreated EndoC-βH1 cells incubated in LG (p<0.05) or HG (p<0.01) 251 
conditions. The GLP-1 analogue, exenatide, used as a positive control, also significantly 252 
stimulated insulin secretion (p<0.01) by the untreated EndoC-βH1 cells (Fig. 5C). 253 
Conversely, when the cells were treated for 96 h with palmitate, the insulinotropic effect of 254 
26RFa was totally abolished whatever the glucose concentration in the culture medium (Fig. 255 
5D). By contrast, exenatide still significantly stimulated insulin secretion by palmitate-treated 256 
cells (p<0.01, Fig. 5D). Comparison of insulin secretion between native and palmitate-treated 257 
EndoC-βH1 cells revealed that, in non-stimulated conditions, basal insulin release was not 258 
affected in palmitate-treated cells (Fig. 5E). By contrast, under stimulatory conditions (26RFa 259 
or exenatide), insulin secretion was dramatically altered in palmitate-treated cells as compared 260 
to native cells (Fig. 5E). Finally, expression of GLUT-1, GLUT-2, the GLP-1 receptor and 261 
GPR103 was evaluated in native and palmitate-treated EndoC-βH1 cells (Fig. 5F). GLUT-1 262 
and the GLP-1 receptor mRNA levels were not altered by the lipotoxic treatment of the cells 263 
(Fig. 5F). By contrast, expression of GLUT-2 was significantly decreased (p<0.05) in 264 
palmitate-treated cells and that of GPR103 was also lowered (p=0.06; Fig. 5F). Consistent 265 
with this latter observation, immunohistochemical observation of pancreas of mice fed a 266 
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standard chow and HF mice revealed a decrease in the intensity of the GPR103 labeling in the 267 
pancreatic islets of HF mice (Fig. 5G, H). 268 
Effect of the high fat diet on gut 26RFa production. We first investigated the expression 269 
and distribution of 26RFa in the duodenum of HF mice and mice fed a standard chow using a 270 
Q-PCR approach combined with immunohistochemistry (Fig. 6A, B).  The expression of 271 
26RFa was significantly lowered (p<0.01) in the duodenum of HF mice as compared to mice 272 
fed a standard chow (Fig. 6A). In agreement with this finding, the immunohistochemistry 273 
revealed an important decrease in the number of enterocytes immunostained with the 26RFa 274 
antibody in the duodenum of HF mice (Fig. 6B). 275 
The impact of a 2 g/kg oral glucose load on plasma glucose, insulin and 26RFa, and on 276 
26RFa content in the duodenum was investigated in HF mice and mice fed a standard chow 277 
(Fig. 6C-G). In mice fed a standard chow, the oral glucose challenge induced an important 278 
increase of the glycemia at 30 min, followed by a decrease at 120 min (Fig. 6C). The HF mice 279 
exhibited a similar glycemic profile although plasma glucose levels were significantly higher 280 
all along the test (p<0.05-0.01; Fig. 6C). Measurement of plasma insulin during the OGTT 281 
indicated that insulinemia was always higher in HF mice as compared to mice fed a standard 282 
chow, as assessed by the point by point statistical analysis (p<0.05-0.001) and the 283 
measurement of the area under the curve (p<0.01) (Fig. 6D). Plasma 26RFa profile in mice 284 
fed a standard chow was very similar to that observed for glycemia and insulinemia, with an 285 
increase of plasma 26RFa levels observed at 30 min followed by a decrease at 120 min (Fig. 286 
6E). In HF mice, plasma 26RFa concentration was similar to that of mice fed a standard chow 287 
during the first 30 min of the test, but the obese/hyperglycemic mice exhibited a dramatic rise 288 
in plasma 26RFa levels at 120 min (p<0.05) that was not observed in mice fed a standard 289 
chow (Fig. 6E), as underlined by the significant difference of the areas under the curves (Fig. 290 
6F). Quantification of 26RFa content in the duodenum showed a significant decrease (p<0.01) 291 
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of the neuropeptide production in HF mice under basal condition (at T0) (Fig. 6G). During the 292 
oral glucose tolerance test, 26RFa content in the duodenum exhibited a profile closely related 293 
to that of plasma 26RFa in the two groups of mice with, in particular, a highly significant rise 294 
of duodenal 26RFa production (p<0.001) 120 min after the oral glucose challenge in HF mice 295 
(Fig. 6G).  296 
297 
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DISCUSSION 298 
 299 
In the first part of the present study, we took advantage of the first disclosed GPR103 300 
antagonist (10) that can be used as an in vivo tool to decipher the role of 26RFa in glucose 301 
homeostasis. We have previously demonstrated that 26RFa could be considered as a novel 302 
incretin (26). This conclusion was based on experiments carried out by our team showing that 303 
26RFa is secreted by the gut in response to an oral glucose load, and that the neuropeptide 304 
stimulates insulin secretion from pancreatic β cells, leading to an anti-hyperglycemic effect 305 
(26). However, without a specific antagonist molecule, it is difficult to isolate the proper role 306 
of 26RFa on the glycemic status from the well-known effects of the other incretins such as 307 
GLP-1 and GIP during an oral glucose challenge, which is recognized as the gold standard 308 
test to assess the effects of incretin hormones. Here, we further characterized the role of 309 
26RFa in the global regulation of glucose homeostasis using a GPR103 antagonist with 310 
DMPK properties suitable for in vivo experiments, namely 25e (10). In our set of experiments, 311 
administration of 25e induced a robust hyperglycemic effect during an oral glucose load in 312 
mice fed a standard chow. We also found that administration of the 26RFa receptor antagonist 313 
significantly reduces insulin sensitivity, confirming that one mechanism of action of the 314 
26RFa/GPR103 system to control glucose homeostasis is to increase insulin sensitivity in 315 
addition to its incretin activity (26). There was a tendency for 25e to increase plasma insulin 316 
levels during a glucose challenge. We hypothesize that this may reflect the occurrence of a 317 
compensatory mechanism to counteract the insulin-resistant effect of the GPR103 antagonist. 318 
However, this increase of insulin secretion is not sufficient to maintain normoglycemia, 319 
suggesting that blockade of 26RFa action also alter the insulin secreting capacity of the 320 
pancreatic islets. Conversely, we show that exogenous administration of 26RFa during an oral 321 
glucose load significantly reduces the hyperglycemia without any significant alteration of the 322 
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plasma insulin levels. In this experiment, it is important to note that, in fact, we have analyzed 323 
the effects of both exogenous and endogenous 26RFa. Thus, it seems that exogenous 324 
administration of 26RFa could potentiate the antihyperglycemic effect already induced by 325 
endogenous 26RFa production. We may speculate that the decrease of the glycemia induced 326 
by exogenous 26RFa is rather linked to an alteration of the insulin sensitivity than insulin 327 
secretion since no modification of plasma insulin levels was observed. Together, these 328 
findings confirm our previous data (26) and support the view that the 26RFa/GPR103 system 329 
plays a crucial role to sustain normoglycemia in stimulatory conditions. 330 
The second objective of the present study was to investigate whether an obese/chronic 331 
hyperglycemic status is associated with a dysfunction of the 26RFa/GPR103 system. For this 332 
purpose, we submitted mice to a HF diet for a period of three months. Measurement of weight 333 
and glycemia revealed that the HF mice were actually obese and intolerant to glucose. 26RFa 334 
did not affect basal plasma glucose levels neither in the HF mice nor in control animals. This 335 
observation is consistent with the incretin status of the neuropeptide previously reported (26). 336 
By contrast, we found that the anti-hyperglycemic effect of 26RFa observed during a glucose 337 
tolerance test in control mice was lost in HF mice. We previously showed that the anti-338 
hyperglycemic effect of 26RFa was the result of both increased insulin sensitivity in target 339 
tissues and a direct stimulation of insulin production by the pancreatic β cells (26). Here, we 340 
show that during an insulin tolerance test, the beneficial effect of 26RFa on insulin sensitivity 341 
is significantly attenuated. This was probably due to the fact that the expression of GPR103 342 
mRNA was down-regulated in muscle and adipose tissues of HF mice compared to controls. 343 
In the in vivo experiments, we found that the stimulatory effect of 26RFa on insulin 344 
production was totally lost in the HF mice. We have previously shown that 26RFa exerts a 345 
direct insulinotropic effect on pancreatic β cells via activation of GPR103 (26). In this study, 346 
we used a human β pancreatic cell line that expresses GPR103 (i.e., EndoC-βH1cells) to 347 
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further explore the direct effects of 26RFa on insulin secretion. We show that 26RFa robustly 348 
stimulates insulin release by these cells. Treatment of the EndoC-βH1cells with palmitate, that 349 
mimics conditions of lipotoxicity observed in diabetes, totally abolished the insulinotropic 350 
effect of 26RFa. By contrast, the GLP-1 analogue, exenatide, was still able to stimulate 351 
insulin release (albeit with a reduced potency) under the same lipotoxic conditions. This latter 352 
observation is in agreement with previous studies showing a reduction of GLP-1-induced 353 
insulin secretion under conditions of lipo and glucotoxicity induced by a HF diet (12).  354 
Finally, we show that the expression of the 26RFa receptor is lowered in the EndoC-βH1cells 355 
cultured in lipotoxic conditions as well as in the pancreatic islets of HF mice, suggesting that 356 
this decreased expression of GPR103 in β-cells is responsible, at least in part, for the loss of 357 
the insulinotropic effect of 26RFa in obese/hyperglycemic conditions. In accordance with 358 
these findings, a loss of GIP insulinotropic effect has also been reported in type 2 diabetes 359 
(13,19) and down-regulation of the GIP receptor has been proposed as one of the mechanisms 360 
underlying the lack of GIP activity in type 2 diabetic patients (1, 17, 24).  Similarly, a down-361 
regulation of the GLP-1 receptor has been described in pancreatic β cells under diabetic 362 
conditions that may underlie the reduced incretin effect of GLP-1 in diabetes (17). However, 363 
some studies suggest that the loss or altered incretin effect in type 2 diabetes is a consequence 364 
of the diabetic state and not a primary event and that the incretin defect is mainly a 365 
consequence of general β cell dysfunction (8, 13, 17, 18). Together, these observations 366 
support the idea that the altered insulinotropic activity of the incretins in diabetes is probably 367 
the result of a down-regulation of their receptor expression in β-cells associated with a 368 
dysfunction of insulin synthesis and production. 369 
We have previously found that the enterocytes of the duodenum are the main source of 370 
peripheral 26RFa and that its release to the general circulation is increased after an oral 371 
glucose challenge (26). Here, we show that, after an overnight fasting, the expression and 372 
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production of 26RFa in the duodenum is significantly decreased in HF mice. This finding, 373 
together with the low expression of the 26RFa receptor in insulin target tissues in HF mice, 374 
suggests that the 26RFa/GPR103 peptidergic system is markedly altered under obese/chronic 375 
hyperglycemic condition. However, we concurrently show that, under stimulatory conditions 376 
(an oral glucose load), the duodenum of HF mice keeps its ability to produce and secrete large 377 
amounts of 26RFa in the general circulation and is even over-stimulated as compared to 378 
control mice. Indeed, in HF mice, plasma 26RFa levels still increase 2 h after the oral glucose 379 
load whereas, in mice fed a standard chow, they return to basal values as previously reported 380 
(26). Interestingly, this plasma 26RFa profile during the OGTT in HF animals follows that of 381 
duodenal 26RFa production suggesting that the duodenum is the main source of circulating 382 
26RFa. In addition, these high plasma 26RFa levels 2 h after glucose ingestion might reflect 383 
the occurrence of a mechanism of action involving 26RFa production by the gut, aiming at 384 
decreasing glycemia. In this context, it would be interesting to investigate whether insulin, 385 
whose plasma levels also remain high 2 h after the oral glucose challenge in HF mice, could 386 
regulate 26RFa production by the gut as the hormone has already been reported to be able to 387 
regulate glucose intestinal absorption, in addition to its peripheral effects (31). It is 388 
noteworthy that this discrepancy in the plasma 26RFa profile during an oral glucose tolerance 389 
test between normal and chronic hyperglycemic conditions is not found for GLP-1 and GIP 390 
(2) and thus seems to be a specificity of 26RFa that deserves further investigation. 391 
Finally, we show that administration of the 26RFa receptor antagonist 25e or 26RFa in 392 
obese/hyperglycemic mice has no effect on the glycemic response during an oral glucose 393 
tolerance test or an insulin tolerance test, nor an insulin secretion during an acute glucose-394 
stimulation insulin secretion test. This observation is in agreement with the blunted 26RFa 395 
response we have observed in HF mice and can be linked to the decreased expression of 396 
GPR103 in insulin target tissues and in β pancreatic cells of the HF mice.  397 
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In conclusion, we have confirmed, using a 26RFa receptor antagonist, that the 398 
neuropeptide 26RFa is a key regulator of glucose homeostasis by acting as an incretin and 399 
improving insulin tolerance. Our data also reveal a loss of the incretin and insulin-sensitive 400 
effect of 26RFa in obese/chronic hyperglycemic conditions that is associated with a down-401 
regulation of its receptor. Together, these observations strongly suggest that dysfunction of 402 
the 26RFa/GPR103 system participate to the general reduced incretin effect and insulin 403 
intolerance observed in diabetes. 404 
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LEGENDS TO FIGURES 554 
 555 
Figure 1: Consequence of blocking 26RFa action on glucose and insulin tolerance in 556 
control mice. (A, B) i.p. injection of the GPR103 antagonist 25e at a dose of 5 mg/kg 557 
significantly increases the blood glucose level during an oral glucose tolerance test (A, insert). 558 
During the same test, plasma insulin concentrations tend to be higher all along the test in 559 
animals that received the GPR103 antagonist (B), although statistical analysis does not reveal 560 
any significant difference between treated and non-treated animals (B insert). (C) 561 
Administration of 25e during an insulin tolerance test significantly reduces insulin sensitivity 562 
from 15 to 90 min after the i.p. injection of insulin. (D, E) i.p. administration of 26RFa (500 563 
µg/kg) reduces significantly the hyperglycemia induced by a 2-g/kg oral glucose challenge 564 
(D), but without affecting plasma insulin levels (E). (Inserts) Calculation of the areas under 565 
the curves. Data represent means ± SEM of 3 independent experiments (n=10-15/group). *, 566 
p<0.05; **, p<0.01; *** p<0.001 vs non-treated animals. 567 
 568 
Figure 2: Effect of 26RFa on basal glycemia and glucose-induced hyperglycemia. (A, B) 569 
A 3-month high fat diet induces a highly significant weight gain (A) and increase of glycemia 570 
(B) right from the first month of treatment as compared to mice fed a standard chow. (C, D) 571 
Effect of i.p. administration of 26RFa (500 µg/kg) on basal plasma glucose levels. 26RFa 572 
does not alter basal plasma glucose during the 90 min following its injection neither in mice 573 
fed a standard chow (C) nor in HF mice (D). (E, F) Effect of i.p. administration of 26RFa 574 
(500 µg/kg) during a glucose tolerance test. 26RFa significantly attenuates the hyperglycemia 575 
induced by the i.p. injection of glucose (1.5 g/kg) throughout the duration of the test in mice 576 
fed a standard chow (E). In HF mice, the anti-hyperglycemic effect of 26RFa during the 577 
glucose tolerance test is totally abolished (F). Calculation of the areas under the curves reveal 578 
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no significant difference between the PBS and the 26RFa groups whatever the type of diet 579 
given (inserts). Data represent means ± SEM of 5 independent experiments (n=20/group). ns, 580 
non significant; *, p<0.05; **, p<0.01; ***, p<0.001 vs mice fed a standard chow. 581 
 582 
Figure 3: Effect of 26RFa on insulin tolerance. (A-C) i.p. administration of 26RFa (500 583 
µg/kg) during an insulin tolerance test significantly potentiates insulin-induced hypoglycemia 584 
during the 90 min following the insulin load (0.75 Units/kg) in mice fed a standard chow (A) 585 
as illustrated by the quantification of the areas under the curves (C) whereas, in HF mice, the 586 
beneficial effect of 26RFa on insulin sensitivity is strongly attenuated (B, C). Data represent 587 
means ± SEM of 5 independent experiments (n=20/group). (D) Expression of GPR103 588 
mRNA was determined by quantitative polymerase chain reaction and adjusted to the signal 589 
intensity of GAPDH in the muscle, the adipose tissue and the liver. GPR103 mRNA levels are 590 
significantly lowered in the muscle and adipose tissue of HF mice as compared to those 591 
measured in mice fed a standard chow. No expression of GPR103 is detected in the liver of 592 
control or HF mice. Data represent means ± SEM of 3 independent experiments (n=6-593 
9/group). *, p<0.05 vs mice fed a standard chow. 594 
 595 
Figure 4: Consequence of blocking 26RFa action on glucose and insulin tolerance in HF 596 
mice. (A, B) Administration of the GPR103 antagonist 25e (5 mg/kg) during an oral glucose 597 
tolerance test in HF mice has no significant effect on plasma glucose (A) and insulin levels 598 
(C), as assessed by the calculation of the areas under the curves (inserts). (C) Similarly, i.p. 599 
injection of 25e does not alter insulin sensitivity during an insulin tolerance test in HF mice. 600 
(D, E) i.p. administration of 26RFa (500 µg/kg) has no significant effect on the 601 
hyperglycemia induced by an oral glucose challenge in HF mice (2 g/kg) (D), nor on plasma 602 
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insulin levels (E). (Inserts) Calculation of the areas under the curves. Data represent means ± 603 
SEM of 3 independent experiments (n=10-12/group). 604 
 605 
Figure 5: Effect of 26RFa on insulin production. (A, B) 26RFa (500 µg/kg) stimulates 606 
significantly glucose-induced insulin production during an acute glucose (1.5 g/kg)-stimulated 607 
insulin secretion test in mice fed a standard chow (A), whereas injection of the neuropeptide 608 
has no effect on plasma insulin in HF mice (B). Data represent means ± SEM of 5 609 
independent experiments (n=20/group). (C, D) Effect of 26RFa (10-6 M) on insulin secretion 610 
by the human pancreatic β cell line EndoC-βH1non treated or treated by palmitate for 96 h. 611 
26RFa significantly stimulates insulin secretion in untreated EndoC-βH1 cells incubated in a 612 
low glucose (LG) or a high glucose (HG) medium (C). Conversely, when the cells are treated 613 
with palmitate, the insulinotropic effect of 26RFa is abolished whatever the glucose 614 
concentration in the culture medium (D). Data represent means ± SEM of 4 independent 615 
experiments (n=10/condition). (E) Comparison of insulin secretion between native and 616 
palmitate-treated EndoC-βH1 cells. In non-stimulatory conditions, insulin release is not 617 
affected in palmitate-treated cells as compared to native cells. By contrast, under stimulatory 618 
conditions (26RFa or exenatide), the secreting response of the cells is significantly altered by 619 
the palmitate treatment. Data represent means ± SEM of 4 independent experiments 620 
(n=10/condition). (F) Expression of the glucose transporters GLUT-1 and GLUT-2, the GLP-621 
1 receptor (GLP1R) and GPR103 mRNA was determined in native EndoC-βH1 cells and in 622 
palmitate-treated EndoC-βH1 cells by quantitative polymerase chain reaction and adjusted to 623 
the signal intensity of cyclophilin A. GLUT-1 and the GLP1R mRNA levels are not altered by 624 
the lipotoxic treatment of the cells whereas the expression of GLUT-2 and GPR103 is 625 
decreased in palmitate-treated cells. Data represent means ± SEM of 3 independent 626 
experiments (n=6-9/group). *, p<0.05; **, p<0.01. (G, H) Immunohistochemical labeling of 627 
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pancreatic islets of control and HF mice with GPR103 antibodies. Representative 628 
photomicrographs of pancreatic islets showing a robust decrease in the intensity of the 629 
GPR103 labeling in the pancreatic islets of HF mice (H) as compared to the pancreatic islets 630 
of mice fed a standard chow (G).  Scale bars: 50 µm. 631 
 632 
Figure 6: Effect of the high fat diet on gut 26RFa production. (A, B) Expression and 633 
distribution of 26RFa in the duodenum of control and HF mice. Expression of 26RFa mRNA 634 
in the duodenum was determined by quantitative polymerase chain reaction and adjusted to 635 
the signal intensity of GAPDH, and its distribution was determined by 636 
immunohistochemistry. The expression of 26RFa is significantly lower in the duodenum of 637 
HF mice as compared to mice fed a standard chow (A). In agreement with this finding, the 638 
immunohistochemistry reveals an important decrease in the number of enterocytes 639 
immunostained with the 26RFa antibody in the duodenum of HF mice in comparison to 640 
duodenal slices of mice fed a standard chow (B). Scale bars: 50 µm. (C-G) Impact of a 2-g 641 
oral glucose load on plasma glucose, insulin and 26RFa, and on 26RFa content in the 642 
duodenum of HF mice and mice fed a standard chow. During an oral glucose challenge, the 643 
HF mice exhibit a similar glycemic profile to that of mice fed a standard show, although their 644 
plasma glucose levels are significantly higher all along the test (C). Measurement of plasma 645 
insulin during the same test reveals that insulinemia is always higher in HF mice as compared 646 
to mice fed a standard chow, as assessed by the point by point statistical analysis and the 647 
calculation of the areas under the curves (D). In HF mice, plasma 26RFa concentration is 648 
similar to that of mice fed a standard chow during the first 30 min of the test, but the 649 
obese/diabetic mice exhibit a dramatic rise in plasma 26RFa levels at 120 min that is not 650 
observed in mice fed a standard chow (E), as underlined by the significant difference of the 651 
areas under the curves (F). Quantification of 26RFa concentration in the duodenum reveals 652 
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lower duodenal 26RFa content in HF mice under basal condition (G). During the oral glucose 653 
tolerance test, 26RFa content in the duodenum exhibits a profile closely related to that of 654 
plasma 26RFa in mice fed a standard chow as well as in HF mice with, in particular, a 655 
significant rise of duodenal 26RFa production 30 and 120 min after the oral glucose challenge 656 
in obese/diabetic animals (G). Data represent means ± SEM of 5 independent experiments 657 
(n=18-20/group). *, p<0.05; **, p<0.01; ***, p<0.001 vs mice fed a standard chow. §, 658 
p<0.05; §§, p<0.01 vs T0 min. 659 
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Forward primer Reverse primer 
Human GPR103 GAAAGGCACCAGGGACTTGT CCAGACCACACCTAGCATTGT 
Human GLP-1 rec TGAGCATAGGCTGGGGTGTT CAGCCGGATAATGAGCCAGT 
Human Glut-1 TGGCATCAACGCTGTCTTCT AGCCAATGGTGGCATACACA 
Humain Glut-2 CTAGTCAGGTGCATGTGCCA AGGGTCCCAGTGACCTTATCT 
Mouse GPR103 GGACGAAGGGCACCATCTT CGTCACGATGCTCCAGAACA 
Mouse 26RFa TCTGCCGTCCTTACCATCTCA TCTCAGGACTGTCCCAAAGGAG 
Mouse GAPDH TCCGGACGCACCCTCAT CGGTTGACCTCCAGGAAATC 
Human cyclophilin A ATGGCACTGGTGGCAAGTCC TTGCCATTCCTGGACCCAAA 
Table 1 - Sequence of the primers used for the Q-PCR experiments 
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